Evidence map›Paper›PMID 40504770›Full record

ArticlePLoS biology2025

Mutant EZH2 alters the epigenetic network and increases epigenetic heterogeneity in B cell lymphoma.

Ofir Griess, Noa Furth, Nofar Harpaz, Nicoletta Di Bernardo, Tomer-Meir Salame, Bareket Dassa, Ioannis Karagiannidis, Yusuke Isshiki, Menachem Gross, Ari M Melnick and 3 more

Abstract read
In one paragraph

Article in PLoS biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Ofir GriessThe Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
Noa FurthThe Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
Nofar HarpazThe Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
Nicoletta Di BernardoThe Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
Tomer-Meir SalameMass Cytometry Unit, Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
Bareket DassaBioinformatics Unit, Department of Life Sciences Core Facilities, Faculty of Biochemistry, Weizmann Institute of Science, Rehovot, Israel.
Ioannis KaragiannidisDivision of Hematology, Weill Cornell Medical College, New York, New York, United States of America.
Yusuke IsshikiDivision of Hematology, Weill Cornell Medical College, New York, New York, United States of America.
Menachem GrossDepartment of Otolaryngology-Head and Neck Surgery, Hadassah Medical Center, Jerusalem, Israel.
Ari M MelnickDivision of Hematology, Weill Cornell Medical College, New York, New York, United States of America.
Wendy BéguelinDivision of Hematology, Weill Cornell Medical College, New York, New York, United States of America.
Guy RonRacah Institute of Physics, Hebrew University of Jerusalem, Jerusalem, Israel.
Efrat ShemaThe Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-3718-593X

Funding

Emerson CollectiveEuropean Research CouncilIsrael Cancer Research FundIsraeli Council for Higher Education (CHE)Minerva foundationThe Israeli Science Foundation
6 · The paper itself

Abstract

Diffuse large B cell lymphomas and follicular lymphomas show recurrent mutations in epigenetic regulators; among these are loss-of-function mutations in KMT2D and gain-of-function mutations in EZH2. To systematically explore the effects of these mutations on the wiring of the epigenetic network, we applied a single-cell approach to probe a wide array of histone modifications. We show that mutant-EZH2 elicits extensive effects on the epigenome of lymphomas, beyond alterations to H3K27 methylations, and is epistatic over KMT2D mutations. Utilizing the single-cell data, we present computational methods to measure epigenetic heterogeneity. We identify an unexpected characteristic of mutant-EZH2, but not KMT2D, in increasing heterogeneity, shedding light on a novel oncogenic mechanism mediated by this mutation. Finally, we present tools to reconstruct known interactions within the epigenetic network, as well as reveal potential novel cross talk between various modifications, supported by functional perturbations. Our work highlights novel roles for mutant-EZH2 in lymphomagenesis and establishes new concepts for measuring epigenetic heterogeneity and intra-chromatin connectivity in cancer cells.

Indexed as

Enhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticGene Regulatory NetworksLymphoma, B-CellAnimalsCell Line, TumorDNA-Binding ProteinsGene Expression Regulation, NeoplasticGerminal CenterHistonesHumansMaleMiceMutationNeoplasm ProteinsProto-Oncogene Proteins c-bcl-6BCL6 protein, humanDNA-Binding ProteinsEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanHistonesKMT2D protein, humanNeoplasm ProteinsProto-Oncogene Proteins c-bcl-6

Identifiers

PMID40504770
PMCPMC12161531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.